Back to first-pass browser

First-pass extracted concept

osteosarcoma

Candidate: concept label2 source documents4 linked claims

Jump to explainers Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Aliases

OS

Extracted Explainers

What the tool is doing

Osteosarcoma is the disease context in which the review discusses NF-κB pathway activation, progression, metastasis, and therapeutic targeting.

Source 2DOI PubMed

Evidence Snippets

Osteosarcoma (OS) and rhabdomyosarcoma (RMS) are the most prevalent pediatric sarcoma subtypes of the bones and soft tissues respectively.

Evidence 1Source 1DOI PubMedprovenance

Studies have confirmed that the NF-κB signaling pathway is an important driver of osteosarcoma.

Evidence 2Source 2DOI PubMedprovenance

Supporting Sources

Source 1primary paper2025MEDDOI PubMed

1 evidence snippet 1 linked claim Claim 1

Source 2primary paper2025MEDDOI PubMed

1 evidence snippet 3 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1development statussupports2025Source 1DOI PubMed

CAR-based treatment for osteosarcoma and rhabdomyosarcoma has been investigated in pre-clinical studies, and first promising clinical trial results have recently been published.

Claim 2disease mechanismsupports2025Source 2DOI PubMed

The NF-κB signaling pathway is an important driver of osteosarcoma.

Claim 3pathway effectsupports2025Source 2DOI PubMed

Abnormal activation of the NF-κB pathway in osteosarcoma promotes cell proliferation, inhibits apoptosis, and enhances migration, invasion, and immune escape.

Claim 4therapeutic rationalesupports2025Source 2DOI PubMed

Inhibition of the NF-κB pathway can inhibit or reverse pathological processes associated with osteosarcoma progression.